Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Haemonetics Corp (NYSE: HAE) closed at $81.11 in the last session, up 0.88% from day before closing price of $80.4. In other words, the price has increased by $0.88 from its previous closing price. On the day, 1.04 million shares were traded. HAE stock price reached its highest trading level at $81.38 during the session, while it also had its lowest trading level at $79.92.
Ratios:
We take a closer look at HAE’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.83. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.64. In the meantime, Its Debt-to-Equity ratio is 1.44 whereas as Long-Term Debt/Eq ratio is at 1.08.
On December 11, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $88.
Raymond James Downgraded its Strong Buy to Outperform on August 11, 2025, while the target price for the stock was maintained at $78.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 10 ’25 when KROLL MARK W bought 1,400 shares for $70.56 per share. The transaction valued at 98,784 led to the insider holds 24,757 shares of the business.
Llorens Josep bought 18,630 shares of HAE for $1,396,132 on Jun 26 ’25. On Jun 12 ’25, another insider, Strong Stewart W, who serves as the Former Officer of the company, bought 708 shares for $71.46 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3907657216 and an Enterprise Value of 4724819456. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.66, and their Forward P/E ratio for the next fiscal year is 14.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.47. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.86 while its Price-to-Book (P/B) ratio in mrq is 4.47. Its current Enterprise Value per Revenue stands at 3.558 whereas that against EBITDA is 13.113.
Stock Price History:
The Beta on a monthly basis for HAE is 0.29, which has changed by 0.020693183 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, HAE has reached a high of $87.32, while it has fallen to a 52-week low of $47.31. The 50-Day Moving Average of the stock is 22.91%, while the 200-Day Moving Average is calculated to be 26.03%.
Shares Statistics:
According to the various share statistics, HAE traded on average about 964.23K shares per day over the past 3-months and 892830 shares per day over the past 10 days. A total of 46.75M shares are outstanding, with a floating share count of 46.05M. Insiders hold about 1.62% of the company’s shares, while institutions hold 111.24% stake in the company. Shares short for HAE as of 1764288000 were 3621526 with a Short Ratio of 3.76, compared to 1761868800 on 3123353. Therefore, it implies a Short% of Shares Outstanding of 3621526 and a Short% of Float of 10.38.
Earnings Estimates
The stock of Haemonetics Corp (HAE) is currently being evaluated by 11.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $1.3, with high estimates of $1.34 and low estimates of $1.25.
Analysts are recommending an EPS of between $4.95 and $4.85 for the fiscal current year, implying an average EPS of $4.91. EPS for the following year is $5.47, with 10.0 analysts recommending between $5.62 and $5.3.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $331.9M. It ranges from a high estimate of $336M to a low estimate of $327.7M. As of. The current estimate, Haemonetics Corp’s year-ago sales were $348.54MFor the next quarter, 11 analysts are estimating revenue of $337.42M. There is a high estimate of $343.6M for the next quarter, whereas the lowest estimate is $332.77M.
A total of 11 analysts have provided revenue estimates for HAE’s current fiscal year. The highest revenue estimate was $1.32B, while the lowest revenue estimate was $1.31B, resulting in an average revenue estimate of $1.32B. In the same quarter a year ago, actual revenue was $1.36BBased on 10 analysts’ estimates, the company’s revenue will be $1.4B in the next fiscal year. The high estimate is $1.42B and the low estimate is $1.37B.
